$0.3860
0.0616.72%
At close: -
$0.3900
0.004001.04%
After Hours: 7:39 PM EDT
Comments
Loading...
Elevation Oncology Analyst Ratings and Price Targets | NASDAQ:ELEV | Benzinga
Elevation Oncology Inc has a consensus price target of $4.22 based on the ratings of 12 analysts. The high is $8 issued by Wedbush on May 3, 2024. The low is $0.7 issued by Piper Sandler on March 21, 2025. The 3 most-recent analyst ratings were released by Stephens & Co., Piper Sandler, and Citizens Capital Markets on March 24, 2025, March 21, 2025, and March 21, 2025, respectively. With an average price target of $2.9 between Stephens & Co., Piper Sandler, and Citizens Capital Markets, there's an implied 643.59% upside for Elevation Oncology Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Stephens & Co.
Piper Sandler
Citizens Capital Markets
Leerink Partners
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Elevation Oncology
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/24/2025 | Buy Now | 156.41% | Stephens & Co. | Sudan Loganathan27% | $5 → $5 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/21/2025 | Buy Now | 79.49% | Piper Sandler | Biren Amin40% | $10 → $0.7 | Downgrade | Overweight → Neutral | Get Alert |
| 03/21/2025 | Buy Now | 1694.87% | Citizens Capital Markets | Silvan Tuerkcan45% | $7 → $7 | Downgrade | Market Outperform → Market Perform | Get Alert |
| 03/21/2025 | Buy Now | 156.41% | Leerink Partners | Andrew Berens49% | $9 → $1 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/21/2025 | Buy Now | 156.41% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $1 | Maintains | Buy | Get Alert |
| 03/10/2025 | Buy Now | 1694.87% | Citizens Capital Markets | Silvan Tuerkcan45% | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/10/2025 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2025 | Buy Now | 1182.05% | Stephens & Co. | Sudan Loganathan27% | $5 → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 01/14/2025 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2025 | Buy Now | — | William Blair | Andy Hsieh20% | — | Initiates | → Outperform | Get Alert |
| 12/19/2024 | Buy Now | 1694.87% | JMP Securities | Silvan Tuerkcan45% | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/13/2024 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 12/06/2024 | Buy Now | 1182.05% | Stephens & Co. | Sudan Loganathan27% | $5 → $5 | Reiterates | Overweight → Overweight | Get Alert |
| 08/07/2024 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 07/15/2024 | Buy Now | 1694.87% | JMP Securities | Silvan Tuerkcan45% | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/28/2024 | Buy Now | 1694.87% | JMP Securities | Silvan Tuerkcan45% | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/31/2024 | Buy Now | 2464.1% | Piper Sandler | Biren Amin40% | → $10 | Initiates | → Overweight | Get Alert |
| 05/14/2024 | Buy Now | 1951.28% | Stephens & Co. | Sudan Loganathan27% | → $8 | Initiates | → Overweight | Get Alert |
| 05/03/2024 | Buy Now | 1951.28% | Wedbush | Robert Driscoll44% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | 1694.87% | JMP Securities | Silvan Tuerkcan45% | → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/07/2024 | Buy Now | 1951.28% | Wedbush | Robert Driscoll44% | $5 → $8 | Maintains | Outperform | Get Alert |
| 03/01/2024 | Buy Now | 1694.87% | JMP Securities | Silvan Tuerkcan45% | → $7 | Initiates | → Market Outperform | Get Alert |
| 02/20/2024 | Buy Now | 1438.46% | HC Wainwright & Co. | Swayampakula Ramakanth49% | $1.5 → $6 | Maintains | Buy | Get Alert |
| 11/06/2023 | Buy Now | 1182.05% | Wedbush | Robert Driscoll44% | → $5 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | 284.62% | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $1.5 | Initiates | → Buy | Get Alert |
| 06/05/2023 | Buy Now | 1438.46% | Wedbush | Robert Driscoll44% | $4 → $6 | Maintains | Outperform | Get Alert |
| 05/30/2023 | Buy Now | 1951.28% | SVB Securities | Andrew Berens49% | $5 → $8 | Upgrade | Market Perform → Outperform | Get Alert |
| 03/10/2023 | Buy Now | 925.64% | Wedbush | Robert Driscoll44% | → $4 | Reiterates | → Outperform | Get Alert |
| 01/09/2023 | Buy Now | 156.41% | SVB Leerink | Andrew Berens49% | $2 → $1 | Maintains | Market Perform | Get Alert |
| 11/10/2022 | Buy Now | — | JP Morgan | Anupam Rama56% | — | Downgrade | Neutral → Underweight | Get Alert |
| 11/07/2022 | Buy Now | 412.82% | SVB Leerink | Andrew Berens49% | $11 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/19/2022 | Buy Now | 1823.08% | HC Wainwright & Co. | Gobind Singh20% | → $7.5 | Assumes | → Buy | Get Alert |
| 08/08/2022 | Buy Now | — | JP Morgan | Anupam Rama56% | — | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for Elevation Oncology (ELEV) stock?
The latest price target for Elevation Oncology (NASDAQ:ELEV) was reported by Stephens & Co. on March 24, 2025. The analyst firm set a price target for $1.00 expecting ELEV to rise to within 12 months (a possible 156.41% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elevation Oncology (ELEV)?
The latest analyst rating for Elevation Oncology (NASDAQ:ELEV) was provided by Stephens & Co., and Elevation Oncology downgraded their equal-weight rating.
When was the last upgrade for Elevation Oncology (ELEV)?
The last upgrade for Elevation Oncology Inc happened on May 30, 2023 when SVB Securities raised their price target to $8. SVB Securities previously had a market perform for Elevation Oncology Inc.
When was the last downgrade for Elevation Oncology (ELEV)?
The last downgrade for Elevation Oncology Inc happened on March 24, 2025 when Stephens & Co. changed their price target from $5 to $1 for Elevation Oncology Inc.
When is the next analyst rating going to be posted or updated for Elevation Oncology (ELEV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elevation Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elevation Oncology was filed on March 24, 2025 so you should expect the next rating to be made available sometime around March 24, 2026.
Is the Analyst Rating Elevation Oncology (ELEV) correct?
While ratings are subjective and will change, the latest Elevation Oncology (ELEV) rating was a downgraded with a price target of $5.00 to $1.00. The current price Elevation Oncology (ELEV) is trading at is $0.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
